Table 1 Summary of clinical studies of mesenchymal stem cell therapy for liver cirrhosis
Included studies | Study period | Country | Stage of LC | Design | Age(year) | Patients(con/exp) | Cell type | Cell dose | Total dose/kg body weight (average 50Â kg/person) | Administration route | Follow up | Main outcome measures | Cause of LC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mohamadnejad et al. [23] | 2007.7–2010.8 | Iran | ND | RCT | 18–65 | 11, 14 | BM-MSCs | 195 × 107cells | 3.9 × 107cells/kg | Cubital vein of the arm | 3,12 months | MELD score, Child–Pugh, Score, ALB, INR, AST, ALT, | HBV/HCV |
Fang et al. [22] | 2013.5–2017.3 | China | ND | RCT | 18–75 | 53, 50 | HUCB-MSCs | (4.0–4.5) × 108 cells two times | (1.6–1.8) × 107cells/kg | Intravenous | 2,4,8,12,24,36, 48 weeks | ALT, AST, ALB, TBIL, PT, MELD core, Child–Pugh score | HBV |
Suk et al. [26] | 2013.1–2015.11 | Korea | Child–Pugh B-C | RCT | 20–70 | 18, 18, 19 | BM-MSCs | 5 × 107 cells /ml 10 ml two Times | 1 × 107cells/kg | Hepatic artery | 3, 6 months | AST, ALT, TBIL, ALP, GGT, INR, MELD core, Child–Pugh score, ALB | AC |
Salama et al. [25] | 2010.6–2011.10 | Egypt | ND | RCT | 20–60 | 20, 20 | BM-MSCs | 1 × 106cells/kg body weight single time | 1 × 106cells/kg | Intravenous | 2 week,1,3,6 month | Bilirubin, ALB, PC, INR, AST, ALT, | HCV |
El-Ansary et al. [21] | ND | Egypt | Child–Pugh C | RCT | 30–60 | 10, 15 | BM-MSCs | 1 × 106cells/kg body weight | 1 × 106cells/kg | Intravenous | 3,6 months | ALB, TBIL, MELD score | HCV |
Peng et al. [24] | 2005.5–2009.6 | China | ND | RCT | 15–75 | 105, 53 | BM-MSCs | 10 ml | UK | Hepatic artery | 1,2,3,4,12, 24,36,48 weeks | ALT, ALB, TBIL, PT, MELD score | HBV |
Bai et al. [28] | 2009.3–2011.3 | China | Child–Pugh B-C | RCT | ND | 15, 32 | BM-MNCs | 1.0–11.2 × 107cells/ml. 10 ml/h | UK | Hepatic artery | 1 week,1,3,6,12,24 months | TBIL, ALB | HBV/AC |
Amer et al. [27] | 2008.10–2009.6 | Egypt | Child–Pugh C | RCT | 45–60 | 20, 20 | BM-MSCs | 2 × 107 cells, single time | 4 × 105 cells/kg | Hepatic artery | 2 weeks,1,2,4, 6 months | Child–Pugh score, MELD score | HCV |
Li et al. [29] | 2010.11–2013.2 | China | ND | RCT | 18–75 | 72, 36 | HUCB-MSCs | ND | UK | ND | 3-year, 5-year | 3-year and 5-year SR | ND |
Shi et al. [30] | 2010.10–2017.10 | China | ND | RCT | 18–65 | 111, 108 | HUC-MSCs | 5 × 105cells/kg body weight | 5 × 105cells/kg | Intravenous | 2, 4, 8, 12,24,48 week, 24, 48, 60, 75 months | OSR, HCC-free SR | HBV |
Zhang et al. [31] | ND | China | ND | RCT | 25–64 | 15, 30 | HUC-MSCs | 5 × 105cells/kg body weight | 5 × 105cells/kg | Intravenous | 0, 1, 2, 4, 8, 12, 24,36,48 weeks | TBIL, CHE, PTA, INR | HBV |